BridgeBio Pharma Inc
NASDAQ:BBIO
Income Statement
Earnings Waterfall
BridgeBio Pharma Inc
Revenue
|
9.3m
USD
|
Cost of Revenue
|
-2.4m
USD
|
Gross Profit
|
6.9m
USD
|
Operating Expenses
|
-606.3m
USD
|
Operating Income
|
-599.4m
USD
|
Other Expenses
|
-43.8m
USD
|
Net Income
|
-643.2m
USD
|
Income Statement
BridgeBio Pharma Inc
Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
27
N/A
|
41
+52%
|
41
N/A
|
41
N/A
|
22
-46%
|
8
-62%
|
9
+6%
|
63
+620%
|
57
-9%
|
70
+22%
|
71
+2%
|
91
+28%
|
89
-2%
|
78
-12%
|
78
+0%
|
6
-93%
|
9
+66%
|
9
-1%
|
|
Gross Profit | ||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(2)
|
(3)
|
(4)
|
(5)
|
(4)
|
(3)
|
(3)
|
(3)
|
(3)
|
(2)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
24
N/A
|
38
+57%
|
0
N/A
|
0
N/A
|
0
N/A
|
8
N/A
|
0
N/A
|
54
N/A
|
55
+2%
|
67
+22%
|
67
0%
|
86
+29%
|
84
-2%
|
74
-12%
|
75
+1%
|
3
-96%
|
7
+128%
|
7
-1%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(184)
|
(204)
|
(238)
|
(275)
|
(302)
|
(346)
|
(401)
|
(448)
|
(483)
|
(548)
|
(572)
|
(594)
|
(643)
|
(627)
|
(624)
|
(597)
|
(543)
|
(515)
|
(514)
|
(551)
|
(606)
|
|
Selling, General & Administrative |
(44)
|
(54)
|
(61)
|
(74)
|
(94)
|
(110)
|
(131)
|
(143)
|
(146)
|
(157)
|
(165)
|
(175)
|
(192)
|
(191)
|
(181)
|
(166)
|
(143)
|
(131)
|
(130)
|
(135)
|
(151)
|
|
Research & Development |
(140)
|
(147)
|
(178)
|
(202)
|
(208)
|
(233)
|
(268)
|
(304)
|
(337)
|
(391)
|
(407)
|
(419)
|
(451)
|
(436)
|
(443)
|
(431)
|
(399)
|
(385)
|
(384)
|
(416)
|
(456)
|
|
Other Operating Expenses |
0
|
(2)
|
0
|
0
|
0
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(184)
N/A
|
(204)
-11%
|
(238)
-17%
|
(251)
-5%
|
(264)
-5%
|
(305)
-16%
|
(361)
-18%
|
(426)
-18%
|
(474)
-11%
|
(540)
-14%
|
(509)
+6%
|
(539)
-6%
|
(577)
-7%
|
(560)
+3%
|
(538)
+4%
|
(513)
+5%
|
(468)
+9%
|
(440)
+6%
|
(511)
-16%
|
(544)
-7%
|
(599)
-10%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
(1)
|
(5)
|
(10)
|
(15)
|
(21)
|
(19)
|
(23)
|
(27)
|
(33)
|
(40)
|
(41)
|
(41)
|
(46)
|
(56)
|
43
|
36
|
35
|
40
|
(63)
|
(67)
|
(45)
|
|
Non-Reccuring Items |
19
|
17
|
17
|
17
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(23)
|
(31)
|
(36)
|
(44)
|
(24)
|
(20)
|
(15)
|
(8)
|
|
Total Other Income |
(4)
|
(5)
|
(4)
|
(4)
|
(1)
|
1
|
(1)
|
(2)
|
2
|
7
|
11
|
11
|
36
|
22
|
9
|
16
|
(8)
|
(2)
|
9
|
3
|
(1)
|
|
Pre-Tax Income |
(169)
N/A
|
(196)
-16%
|
(235)
-20%
|
(254)
-8%
|
(289)
-14%
|
(323)
-12%
|
(385)
-19%
|
(455)
-18%
|
(505)
-11%
|
(572)
-13%
|
(538)
+6%
|
(569)
-6%
|
(586)
-3%
|
(617)
-5%
|
(517)
+16%
|
(496)
+4%
|
(485)
+2%
|
(426)
+12%
|
(584)
-37%
|
(623)
-7%
|
(653)
-5%
|
|
Net Income | ||||||||||||||||||||||
Income from Continuing Operations |
(169)
|
(196)
|
(235)
|
(254)
|
(289)
|
(323)
|
(385)
|
(455)
|
(505)
|
(572)
|
(538)
|
(569)
|
(586)
|
(617)
|
(517)
|
(496)
|
(485)
|
(426)
|
(584)
|
(623)
|
(653)
|
|
Income to Minority Interest |
39
|
50
|
38
|
28
|
28
|
32
|
39
|
52
|
57
|
53
|
43
|
34
|
24
|
21
|
8
|
6
|
3
|
1
|
11
|
11
|
10
|
|
Net Income (Common) |
(131)
N/A
|
(155)
-18%
|
(197)
-27%
|
(226)
-14%
|
(261)
-15%
|
(291)
-12%
|
(346)
-19%
|
(402)
-16%
|
(449)
-12%
|
(520)
-16%
|
(495)
+5%
|
(535)
-8%
|
(563)
-5%
|
(596)
-6%
|
(509)
+15%
|
(491)
+4%
|
(481)
+2%
|
(425)
+12%
|
(573)
-35%
|
(613)
-7%
|
(643)
-5%
|
|
EPS (Diluted) |
-1.14
N/A
|
-1.34
-18%
|
-1.89
-41%
|
-1.92
-2%
|
-2.48
-29%
|
-2.47
+0%
|
-2.94
-19%
|
-3.41
-16%
|
-3.8
-11%
|
-3.75
+1%
|
-3.37
+10%
|
-3.65
-8%
|
-3.9
-7%
|
-4.08
-5%
|
-3.49
+14%
|
-3.31
+5%
|
-3.26
+2%
|
-2.78
+15%
|
-3.56
-28%
|
-3.75
-5%
|
-3.95
-5%
|